Home > Breast Cancer Information > Facts & Statistics > Research Studies > Research Table Topics > Oral Selective Estrogen Receptor Degraders (SERDs) for Metastatic Breast Cancer Treatment

Research table: Oral selective estrogen receptor degraders (SERDs) for metastatic breast cancer treatment

This summary table contains detailed information about research studies. Summary tables are a useful way to look at the science behind many breast cancer guidelines and recommendations. However, to get the most out of the tables, it’s important to understand some key concepts. Learn how to read a research table.

Introduction: Selective estrogen receptor degraders (SERDs) are a type of hormone therapy. These anti-estrogen drugs bind to the estrogen receptor in a tumor cell. They cause the receptor to be broken down by the cell.

Some SERDs are in pill form (taken orally). Camizestrant (Etcamah), elacestrant (Orserdu) and imlunestrant (Inluriyo) are oral SERDs.

Camizestrant, elacestrant and imlunestrant are used to treat some hormone receptor-positive, HER2-negative metastatic breast cancers that have an ESR1 tumor gene mutation. (The ESR1 mutation is in the genes of the breast cancer cells, not the genes of the person.)

For people with these breast cancers:

  • Taking elacestrant or imlunestrant may increase overall survival better than treatment with another hormone therapy.
  • Taking imlunestrant plus a CDK4/6 inhibitor may increase the time before the cancer worsens better than treatment with imlunestrant alone.
  • Taking camizestrant plus a CDK4/6 inhibitor may increase the time before the cancer worsens better than treatment with an aromatase inhibitor plus a CDK4/6 inhibitor.

Learn more about camizestrant, elacestrant and imlunestrant, including their side effects.

Learn about guidelines for the treatment of metastatic breast cancer.

Learn about the strengths and weaknesses of different types of studies.

Study selection criteria: Randomized clinical trials with 100 or more participants with hormone receptor-positive, HER2-negative metastatic breast cancer with an ESR1 tumor gene mutation.

Study

Study Population
(number of participants)

Drug(s) Used

Progression-free Survival
(survival with no breast cancer spread)

Overall Survival
(95% CI)

Randomized clinical trials

SERENA-6 trial [1]

315

Camizestrant
plus
a CDK4/6 inhibitor

Progression-free survival at 18 months:
40%*,†

Aromatase inhibitor
plus
a CDK4/6 inhibitor

Progression-free survival at 18 months:
14%*,†

EMBER study [2]

256

Imlunestrant

Progression-free survival at 12 months:
25%†

Overall survival at
18 months:
77%†

Fulvestrant or exemestane alone

Progression-free survival at 12 months:
7%†

Overall survival at
18 months:
59%†

EMERALD trial [3]

228

Elacestrant

Progression-free survival at 12 months:
27%†

Overall survival at
1 year:
83%†
   

Fulvestrant, anastrozole, letrozole or exemestane alone

Progression-free survival at 12 months:
8%†

Overall survival at
1 year:
74%†

* Progression-free survival at 2 years was 30% in the camizestrant group and 5% in the aromatase inhibitor group.

† Statistically significant difference between the 2 treatment groups.

References

  1. Bidard FC, Mayer EL, Park JH, et al. for the SERENA-6 Study Group. First-line camizestrant for emerging ESR1-mutated advanced breast cancer. N Engl J Med. 393(6):569-580, 2025.
  2. Jhaveri KL, Neven P, Casalnuovo ML, et al. for the EMBER-3 Study Group. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 392(12):1189-1202, 2025.
  3. Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD Trial. J Clin Oncol. 40(28):3246-3256, 2022.

Updated 10/06/26